Clinical approaches to the development of a neuroprotective therapy for PD.

Clinical approaches to the development of a neuroprotective therapy for PD. Exp Neurol. 2017 Jun 13;: Authors: Olanow CW, Kieburtz K, Katz R Abstract The development of a neuroprotective or disease-modifying therapy is the major unmet need in the management of Parkinson's Disease (PD) and the goal of much clinical and scientific research. However, despite enormous efforts and expense, no disease-modifying therapy for PD has been approved to date. Historically attempts to define such a therapy have been limited by confounding symptomatic/pharmacologic effects of the study intervention and the lack of a clear and well-defined regulatory and clinical development pathway that leads to a disease-modifying indication. Further, the costs of As a consequence, many pharmaceutical companies are reluctant to test novel therapies despite the recent scientific advances and promising candidate targets and approaches. In the present review we describe previous studies aimed at defining a disease-modifying drug and discuss their limitations. We also consider some of the modern approaches and trial design for drug development that will hopefully pave the way toward identifying and gaining regulatory approval for a disease-modifying therapy in a relatively efficient and cost-effective manner. PMID: 28622912 [PubMed - as supplied by publisher]
Source: Experimental Neurology - Category: Neurology Authors: Tags: Exp Neurol Source Type: research

Related Links:

Conclusions: In the context of high judicialization, patients suffering from PD must increasingly use the judicial system to access treatment. To promote more equitable and efficient access benefit packages, developing countries must consider more thoroughly the needs of these patients. PMID: 31627711 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Authors: Chen A, Selvaraj S, Krishnan V, Asgari S Abstract Accurate and reliable detection of the onset of gait initiation is essential for the correct assessment of gait. Thus, this study was aimed at evaluation of the reliability and accuracy of 3 different center of pressure-based gait onset detection algorithms: A displacement baseline-based algorithm (method 1), a velocity baseline-based algorithm (method 2), and a velocity extrema-based algorithm (method 3). The center of pressure signal was obtained during 10 gait initiation trials from 16 healthy participants and 3 participants with Parkinson's disease. Int...
Source: Journal of Applied Biomechanics - Category: Sports Medicine Tags: J Appl Biomech Source Type: research
MONDAY, Oct. 21, 2019 -- Former professional soccer players have a significantly increased risk of death from brain diseases such as Alzheimer's and Parkinson's, a new study finds. Former soccer players were about 3.5 times more likely to die of...
Source: - Daily MedNews - Category: General Medicine Source Type: news
TET2 upregulation has been shown to improve neurogenesis and cognitive function in old mice. So it is interesting that researchers here link increased expression of TET2 with the inflammatory response of microglia in the brain. The broader context is that is becoming increasingly clear that dysfunctional and inflammatory microglia contribute significantly to the progression of neurodegenerative conditions. This is one of many examples of apparently contradictory results to illustrate the point that cellular biochemistry is very complex. Contradictions usually indicate that there is much left to be understood about the way ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Electrochemical biosensors for the detection and study of α-synuclein related to Parkinson's disease - A review. Anal Chim Acta. 2019 Dec 16;1089:32-39 Authors: Hassan Q, Li S, Ferrag C, Kerman K Abstract Parkinson's disease (PD) is a long-term degenerative disorder that affects predominately dopaminergic neurons in the substantia nigra, which mainly control movement. Alpha-synuclein (α-syn) is a major constituent of Lewy bodies that are reported to be the most important toxic species in the brain of PD patients. In this critical review, we highlight novel electrochemical biosensors that h...
Source: Analytica Chimica Acta - Category: Chemistry Authors: Tags: Anal Chim Acta Source Type: research
Discussion and conclusionCrinamine and epibuphanisine exhibited potent and selective inhibitory activity towards MAO-B. After comprehensive in silico investigations encompassing robust molecular docking analysis, the drug-like attributes and safety of the alkaloids suggest the crinamine is a potentially safe drug for human application.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 19 October 2019Source: Stem Cell ResearchAuthor(s): Marija Dulovic-Mahlow, Agnieszka Lukomska, Sokhna Haissatou Diaw, Alexander Balck, Max Borsche, Karen Grütz, Insa Lenz, Franziska Rudolph, Katja Lohmann, Christine Klein, Philip SeiblerAbstractDespite a genetic component in the development of Parkinson´s disease (PD), monozygotic twin pairs often display discordance for PD. Here, we describe the generation of six human induced pluripotent stem cell (iPSC) lines from dermal fibroblasts of three pairs of monozygotic twins discordant for PD. We used non-integrating Sendai virus a...
Source: Stem Cell Research - Category: Stem Cells Source Type: research
Publication date: Available online 20 October 2019Source: Molecular and Cellular NeuroscienceAuthor(s): Navneet Ammal Kaidery, Manuj Ahuja, Bobby ThomasAbstractSearch for a definitive cure for neurodegenerative disorders like Parkinson's disease (PD) has met with little success. Mitochondrial dysfunction and elevated oxidative stress precede characteristic loss of dopamine-producing neurons from the midbrain in PD. The majority of PD cases are classified as sporadic (sPD) with an unknown etiology, whereas mutations in a handful of genes cause monogenic form called familial (fPD). Both sPD and fPD is characterized by protei...
Source: Molecular and Cellular Neuroscience - Category: Neuroscience Source Type: research
Publication date: Available online 18 October 2019Source: Stem Cell ResearchAuthor(s): Ana Joana Duarte, Diogo Ribeiroa, Renato Santos, Luciana Moreira, José Bragança, Olga AmaralAbstractGaucher Disease (GD) type 3 is a neurological form of a multisystemic autosomal recessive disorder belonging to the group of lysosomal storage diseases. Mutations in glucocerebrosidase 1 (GBA1) commonly lead to abnormal protein and GD, heterozygosity is a genetic risk factor for Parkinson's disease. This work describes the use of a non-integrative approach using Sendai Virus delivery to establish iPSCs from fibroblasts from a...
Source: Stem Cell Research - Category: Stem Cells Source Type: research
In this study, the several uses of levodopa electrochemical sensors in areas such as pharmaceutical or clinical evaluation, with levodopa as a vital analyte are reviewed.
Source: Microchemical Journal - Category: Chemistry Source Type: research
More News: Brain | Neurology | Neuroscience | Parkinson's Disease | Study